Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging
Mukesh K. Pandey, Timothy R. DeGrado
Theranostics (2016) Vol. 6, Iss. 4, pp. 571-593
Open Access | Times Cited: 163

Showing 1-25 of 163 citing articles:

Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade
Masha G. Savelieff, Geewoo Nam, Juhye Kang, et al.
Chemical Reviews (2018) Vol. 119, Iss. 2, pp. 1221-1322
Closed Access | Times Cited: 482
RETRACTED ARTICLE: Roles of the PI3K/AKT/mTOR signalling pathways in neurodegenerative diseases and tumours
Fei Xu, Lixin Na, Yanfei Li, et al.
Cell & Bioscience (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 482
GSK3 and its interactions with the PI3K/AKT/mTOR signalling network
Miguel A. Hermida, J. Dinesh Kumar, Nicholas R. Leslie
Advances in Biological Regulation (2017) Vol. 65, pp. 5-15
Closed Access | Times Cited: 392
Anticancer activity of complexes of the third row transition metals, rhenium, osmium, and iridium
Chilaluck C. Konkankit, Sierra C. Marker, Kevin M. Knopf, et al.
Dalton Transactions (2018) Vol. 47, Iss. 30, pp. 9934-9974
Closed Access | Times Cited: 242
Emerging PET Radiotracers and Targets for Imaging of Neuroinflammation in Neurodegenerative Diseases: Outlook Beyond TSPO
Vidya Narayanaswami, Kenneth Dahl, Vadim Bernard‐Gauthier, et al.
Molecular Imaging (2018) Vol. 17
Open Access | Times Cited: 190
Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseases
Li Wang, Jiajia Li, Li‐jun Di
Medicinal Research Reviews (2021) Vol. 42, Iss. 2, pp. 946-982
Open Access | Times Cited: 124
Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward
Sara Arciniegas Ruiz, Hagit Eldar-Finkelman
Frontiers in Molecular Neuroscience (2022) Vol. 14
Open Access | Times Cited: 84
Targeting GSK3 signaling as a potential therapy of neurodegenerative diseases and aging
Przemysław Duda, J. Wisniewski, Tomasz Wójtowicz, et al.
Expert Opinion on Therapeutic Targets (2018) Vol. 22, Iss. 10, pp. 833-848
Closed Access | Times Cited: 109
Revealing quinquennial anticancer journey of morpholine: A SAR based review
Fatima Arshad, Mohemmed Faraz Khan, Wasim Akhtar, et al.
European Journal of Medicinal Chemistry (2019) Vol. 167, pp. 324-356
Closed Access | Times Cited: 105
Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer
Siddavaram Nagini, Josephraj Sophia, Rajakishore Mishra
Seminars in Cancer Biology (2018) Vol. 56, pp. 25-36
Closed Access | Times Cited: 102
Indole-fused azepines and analogues as anticancer lead molecules: Privileged findings and future directions
Ashok Kumar Singh, Vinit Raj, Sudipta Saha
European Journal of Medicinal Chemistry (2017) Vol. 142, pp. 244-265
Closed Access | Times Cited: 90
GSK3β-mediated Keap1-independent regulation of Nrf2 antioxidant response: A molecular rheostat of acute kidney injury to chronic kidney disease transition
Minglei Lu, Pei Wang, Yingjin Qiao, et al.
Redox Biology (2019) Vol. 26, pp. 101275-101275
Open Access | Times Cited: 80
Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy
Thanigaimalai Pillaiyar, Stefan Laufer
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 2, pp. 955-982
Closed Access | Times Cited: 60
PET molecular imaging for pathophysiological visualization in Alzheimer’s disease
Jing Wang, Chentao Jin, Jinyun Zhou, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2022) Vol. 50, Iss. 3, pp. 765-783
Open Access | Times Cited: 40
Therapeutic Potential Effect of Glycogen Synthase Kinase 3 Beta (GSK-3β) Inhibitors in Parkinson Disease: Exploring an Overlooked Avenue
Areej Turkistani, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Molecular Neurobiology (2024) Vol. 61, Iss. 9, pp. 7092-7108
Open Access | Times Cited: 11
Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity
Heba T. Abdel‐Mohsen, Yasmin M. Syam, Mahmoud S. Abd El‐Ghany, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 10
Closed Access | Times Cited: 8
Targeting Wnt signaling pathway with small-molecule therapeutics for treating osteoporosis
Shakir Ahamad, Mohammad Saquib, Mohd Kamil Hussain, et al.
Bioorganic Chemistry (2025) Vol. 156, pp. 108195-108195
Closed Access | Times Cited: 1
Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging
Steven H. Liang, Jinshan Michael Chen, Marc D. Normandin, et al.
Angewandte Chemie International Edition (2016) Vol. 55, Iss. 33, pp. 9601-9605
Open Access | Times Cited: 76
LncRNA MALAT1 modulates ox-LDL induced EndMT through the Wnt/β-catenin signaling pathway
Hongrong Li, Qifei Zhao, Liping Chang, et al.
Lipids in Health and Disease (2019) Vol. 18, Iss. 1
Open Access | Times Cited: 73
Molecular dynamics and structure-based virtual screening and identification of natural compounds as Wnt signaling modulators: possible therapeutics for Alzheimer’s disease
Suman Manandhar, Runali Sankhe, Keerthi Priya, et al.
Molecular Diversity (2022) Vol. 26, Iss. 5, pp. 2793-2811
Open Access | Times Cited: 31
The neurobiology and therapeutic potential of multi-targeting β-secretase, glycogen synthase kinase 3β and acetylcholinesterase in Alzheimer’s disease
Mariana G. Fronza, Diego Alves, Domenico Praticò, et al.
Ageing Research Reviews (2023) Vol. 90, pp. 102033-102033
Closed Access | Times Cited: 21
Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
Suggala Ramya Shri, Suman Manandhar, Yogendra Nayak, et al.
Advanced Pharmaceutical Bulletin (2023) Vol. 13, Iss. 4, pp. 688-700
Open Access | Times Cited: 18
Mitigating lipopolysaccharide-induced impairment in human dental pulp stem cells with tideglusib-doped nanoparticles: Enhancing osteogenic differentiation and mineralization
Raquel Osorio, Francisco Javier Rodríguez‐Lozano, Manuel Toledano, et al.
Dental Materials (2024) Vol. 40, Iss. 10, pp. 1591-1601
Closed Access | Times Cited: 8
Gallic Acid Alleviates Cognitive Impairment by Promoting Neurogenesis via the GSK3β-Nrf2 Signaling Pathway in an APP/PS1 Mouse Model
Yu Ding, Jinrong He, Fanli Kong, et al.
Journal of Alzheimer s Disease Reports (2024) Vol. 8, Iss. 1, pp. 461-477
Open Access | Times Cited: 6
Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
Xiaosheng Wu, Mary Stenson, Jithma P. Abeykoon, et al.
Blood (2019) Vol. 134, Iss. 4, pp. 363-373
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top